Biopharma Innovations: Experts Leveraging Ion Mobility


Join us for an engaging roundtable webinar where experts from the biotechnology industry will discuss the transformative benefits of ion mobility.

This technology provides outstanding resolution, improved throughput, and unparalleled reproducibility, crucial for the analysis of vital biological molecules, including cyclic peptides and peptide therapeutics. 

This is an invaluable opportunity to deepen your understanding of ion mobility, its benefits and how it is propelling the biotechnology sector forward!

Webinar Learning Objectives:

  • Understand the benefits of HRIM in unmasking isomeric analytes like cyclic peptides and other peptide therapeutics.
  • Learn how to achieve reproducibility an order of magnitude better than conventional LC, with increased throughput using ion mobility.
  • Learn about real-world applications from biotechnology experts in the field and the practical applications of ion mobility and how it is shaping future developments.


Komal Kedia, PhD

Associate Principal Scientist , Merck

Dr. Kedia, earned her Ph.D. in Analytical Chemistry from BYU in the lab of Steven Graves followed by a postdoc at PNNL under SLIM inventor, Dick Smith.

Throughout her career, she has led various biomarker research projects. As an associate principal scientist at Merck, she focuses on PK/PD studies and biomarker analysis. She also leads a project developing advanced ion mobility technology to address various analytical challenges.

Phil Lorenzi, PhD

Assoc. Prof., Dir. of Metabolomics Core, Dir. of Proteomics Core , MD Anderson Cancer Center

Dr. Lorenzi is the Director of the Metabolomics Core Facility, Director of the Proteomics Core Facility, and Associate Professor in the Department of Bioinformatics and Computational Biology at The University of Texas MD Anderson Cancer Center.

His background and training are in chemistry, pharmacology, and omic technologies (genomics, transcriptomics, proteomics, and metabolomics). His laboratory develops metabolic therapies for the treatment of cancer.

He collaborates with 200+ investigators per year on projects that span the continuum of drug development and life science research, and has co-authored 94 peer-reviewed publications. His multidisciplinary team provides analytical services in a state-of-the art facility

Chris Crittenden, PhD

Principal Scientist, Biopharma

Dr. Christopher M. Crittenden earned his Ph.D. focusing on ultraviolet photodissociation mass spectrometry applications in biological structures at the University of Texas. Post-Ph.D., he joined Genentech's Small Molecule Analytical Chemistry department, specializing in identifying process-related impurities and confirming structures for IND filings using tandem mass spectrometry.

At Genentech, he explores new technologies and maintains a keen interest in ion activation and novel separation techniques to address biopharmaceutical challenges. Outside the lab, Chris enjoys hiking in the San Francisco Bay Area and watching baseball games with his family.

Greg Kilby, PhD

Distinguished Scientist, MOBILion Systems, Inc

With a distinguished career spanning more than 15 years in biopharmaceutical research, Dr Greg Kilby has emerged as a prominent figure in the realm of molecular analysis and mass spectrometry.

Holding a PhD in analytical chemistry, Greg's expertise encompasses the pioneering application and development of cutting-edge ion mobility-mass spectrometry technologies. His transformative work revolves around harnessing these innovative platforms to decipher intricate biomolecular structures, shedding light on the complexities of peptide therapeutics and biopharmaceuticals.

As an advocate for scientific advancement, Greg's contributions continue to shape the landscape of biopharmaceutical analysis, consistently pushing the boundaries of knowledge and discovery.